While Humira held its ad spending crown yet again in May, Latuda jumped up to knock Lyrica from the No. 2 spot it’s held for the past few months. Sunovion … Continue Reading In May TV spending, Sunovion jumps to 2nd, but AbbVie easily keeps top spot
CHICAGO—Merck’s Keytruda already boasts a standalone approval for lung cancer patients who haven’t been treated before, so long as their tumors bear high levels of the PD-L1 biomarker. But it … Continue Reading ASCO: Merck’s solo Keytruda wins again, but might just leave room for competition
The field of genetics has long been an object of global fascination, beginning with Mendel’s pea plant experiments in the 19th century and peaking when the human genome was sequenced … Continue Reading The Next Generation of Genetic Medicine: A Review of Epigenetics
Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much of it is hype? The pipelines of biotech and pharma are filling up with combination therapies … Continue Reading Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought?